Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edgewise Therapeutics Inc (EWTX)

Edgewise Therapeutics Inc (EWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,598,001
  • Shares Outstanding, K 105,868
  • Annual Sales, $ 0 K
  • Annual Income, $ -133,810 K
  • EBIT $ -181 M
  • EBITDA $ -191 M
  • 60-Month Beta 0.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.64

Options Overview Details

View History
  • Implied Volatility 51.10% (-14.53%)
  • Historical Volatility 114.86%
  • IV Percentile 2%
  • IV Rank 2.79%
  • IV High 270.13% on 10/22/25
  • IV Low 44.82% on 06/26/25
  • Expected Move (DTE 16) 1.91 (7.71%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 153
  • Volume Avg (30-Day) 2,068
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 11,116
  • Open Int (30-Day) 14,467
  • Expected Range 22.91 to 26.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 8
  • High Estimate -0.38
  • Low Estimate -0.48
  • Prior Year -0.42
  • Growth Rate Est. (year over year) -2.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.76 +25.58%
on 12/22/25
27.39 -9.40%
on 12/26/25
-1.23 (-4.70%)
since 11/28/25
3-Month
14.25 +74.14%
on 10/14/25
27.39 -9.40%
on 12/26/25
+8.60 (+52.99%)
since 09/30/25
52-Week
10.60 +134.10%
on 04/07/25
30.48 -18.59%
on 02/06/25
-2.24 (-8.28%)
since 12/30/24

Most Recent Stories

More News
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

–  In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; n o clinically meaningful reductions in LVEF or LVEF

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

–  Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch –

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics...

EWTX : 24.82 (+1.12%)
Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the...

EWTX : 24.82 (+1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

See More

Key Turning Points

3rd Resistance Point 26.16
2nd Resistance Point 25.60
1st Resistance Point 25.21
Last Price 24.82
1st Support Level 24.25
2nd Support Level 23.68
3rd Support Level 23.29

See More

52-Week High 30.48
Last Price 24.82
Fibonacci 61.8% 22.89
Fibonacci 50% 20.54
Fibonacci 38.2% 18.19
52-Week Low 10.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar